GHK-CU vs Snap-8

GHK-CU

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma by Pickart and Thaler in 1973. Its mechanism of action involves delivering bioavailable copper ions to tissues, where copper serves as a cofactor for lysyl oxidase (collagen crosslinking), superoxide dismutase (antioxidant defense), and other metalloenzymes critical for tissue maintenance. GHK-Cu modulates gene expression of over 4,000 human genes, broadly shifting patterns toward tissue remodeling and repair (Pickart et al., BioMed Research International, 2012). Research demonstrates it upregulates collagen types I and III, elastin, decorin, and glycosaminoglycan synthesis while simultaneously downregulating metalloproteinase activity that degrades extracellular matrix. In wound healing studies, GHK-Cu accelerated dermal wound contraction and re-epithelialization in animal models (Leyden et al., Archives of Dermatological Research, 2002). The peptide also shows neuroprotective properties; studies suggest it reduces oxidative damage markers and may support nerve regeneration through NGF and VEGF upregulation. Compared to retinoids and vitamin C in skin research, GHK-Cu operates through a fundamentally different mechanism centered on copper-dependent enzymatic activity and broad transcriptomic remodeling rather than receptor activation or direct antioxidant scavenging. At 100mg, this formulation supports extended research studies. Store lyophilized powder at -20C protected from light; reconstitute with sterile water and refrigerate at 2-8C. GHK-Cu is researched by dermatology departments, cosmetic science laboratories, and neuroscience institutions studying copper-dependent tissue repair and gene regulation.

Snap-8

Snap-8 (acetyl octapeptide-3) is a synthetic eight-amino acid peptide that acts as a competitive antagonist of the SNARE complex, specifically mimicking the N-terminal end of SNAP-25 to interfere with vesicular neurotransmitter release at the neuromuscular junction. By competing with native SNAP-25 for SNARE complex assembly, Snap-8 reduces the exocytosis of acetylcholine from motor neurons, thereby decreasing the intensity of muscle contractions responsible for dynamic expression lines. In vitro studies by Lipotec (now part of Lubrizol) demonstrated that Snap-8 at 0.05 mg/mL reduced SNARE complex formation by approximately 73%, while clinical evaluation showed a mean wrinkle depth reduction of approximately 63% after 28 days of topical application at 10% concentration. This mechanism is analogous to but milder than botulinum toxin, which cleaves SNARE complex proteins irreversibly rather than competing for binding sites. Compared to its predecessor argireline (acetyl hexapeptide-3/Snap-6), Snap-8 contains two additional amino acids that research indicates improve binding affinity and stability. Unlike research-grade neuromodulators, Snap-8 is designed for topical research formulations and does not cross the dermal barrier in quantities sufficient to cause systemic neuromuscular effects. The peptide is water-soluble and compatible with most cosmetic research vehicles. Store lyophilized powder at -20C; for topical research formulations, dissolve in aqueous buffer at desired concentration. Snap-8 is studied by cosmetic chemistry laboratories, dermatological research institutions, and topical drug delivery researchers developing non-invasive cellular-aging formulations.

Frequently Asked Questions